SNOT-22对鼻内镜术后额外阿片类药物处方的预测价值
该回顾性研究纳入2016年11月至2017年8月接受鼻内镜手术的121例患者,其中22例(18.2%)术后60天内需要额外阿片类药物处方。基线SNOT-22总分及耳/面部维度评分在额外处方组更高,且术后相对改善更小,提示术前SNOT-22有助于识别高风险患者。
要点
- 基线SNOT-22总分≥58.7±16.0与术后额外阿片处方风险相关
- 基线耳/面部维度评分高者需额外阿片处方的风险增加
- 术后SNOT-22相对改善而非绝对改善对额外阿片处方更具预测性
核心结论
- 基线耳部和面部症状较多的患者鼻内镜术后需要额外阿片类药物处方的风险增加。
- 术前SNOT-22评分可能有助于识别术后需要额外阿片处方的患者。
- SNOT-22评分的相对改善而非绝对改善对额外阿片处方更具预测性。
研究设计与样本
- 回顾性研究,纳入2016年11月至2017年8月接受鼻内镜手术的患者121例。
- 通过CURES记录识别术后60天内需要额外阿片类药物处方的患者。
- 分析基线和首次术后随访SNOT-22总分及维度评分与额外阿片处方的关联。
主要发现
- 121例患者中22例(18.2%)需要额外阿片类药物处方。
- 额外处方组基线SNOT-22总分更高(58.7±16.0 vs 46.1±22.5,p<0.01)。
- 额外处方组基线耳/面部维度评分更高(11.4±4.8 vs 8.5±5.4,p<0.01)。
- 额外处方组在紧邻术前访视时所有SNOT-22维度评分均更高(p<0.001)。
- 两组绝对改善无差异(15.5±18.30 vs 12.3±23.9,p=0.54),但额外处方组相对改善更小(20.2% vs 34.8%,p<0.05)且平均效应量更小(0.57 vs 0.70,p<0.001)。
临床怎么用
- 术前可依据SNOT-22总分及耳/面部维度评分识别术后可能需要额外阿片类药物的高风险患者。
- 对基线SNOT-22评分较高的患者,术后应加强疼痛管理和阿片类药物使用监测。
局限性
- 回顾性研究设计。
- 样本量有限(121例)。
- 仅通过CURES记录识别额外阿片处方,可能低估实际需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endoscopic sinus surgery (ESS) is generally well tolerated, yet a subset of patients require an additional opiate prescription in the postoperative period. The purpose of this study was to quantify differences in both preoperative and immediate postoperative 22-item Sino-Nasal Outcome Test (SNOT-22) scores between patients with a single prescription and those requiring additional opiate prescriptions (AOPs). METHODS: Patients undergoing ESS between November 2016 and August 2017 were reviewed retrospectively. The Medical and Controlled Substance Utilization Review and Evaluation System (CURES) records were reviewed; patients requiring AOP within 60 days after surgery were identified. The primary and secondary outcomes of interest were the association of baseline and first postoperative visit SNOT-22 total and domain scores with AOP. RESULTS: A total of 121 patients were reviewed, 22 (18.2%) required AOP. Baseline SNOT-22 scores were higher in aggregate (58.7 ± 16.0 vs 46.1 ± 22.5) and ear/facial domain (11.4 ± 4.8 vs 8.5 ± 5.4) in the AOP group (p < 0.01). AOP patients also demonstrated higher scores across all SNOT-22 domains (p < 0.001) at the immediate preoperative visit. There was no difference in the absolute improvement between groups (15.5 ± 18.30 vs 12.3 ± 23.9, p = 0.54). AOP patients experienced less relative improvement (20.2% vs 34.8%, p < 0.05) and smaller mean effect size (0.57 vs 0.70, p < 0.001) after ESS. CONCLUSION: Patients reporting increased ear and facial symptoms at baseline have an increased risk of additional opiate prescription after surgery; preoperative SNOT-22 scores may provide utility in identifying these patients. Subjects in both cohorts report symptomatic improvement after ESS; however, relative, not absolute, improvement in SNOT-22 scores is more predictive of AOP.
引用
- Shen SA, Jafari A, Bracken D, et al. Predictive value of SNOT-22 on additional opiate prescriptions after endoscopic sinus surgery. Int Forum Allergy Rhinol. 2018. PMID: 29722922. doi:10.1002/alr.22137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。